Mulberry Leaf Extract DNJ Clinical Evidence: A B2B Formulator's Perspective

Mulberry leaf extract standardized to 1-deoxynojirimycin (DNJ) has moved from a niche Asian-market ingredient to a mainstream metabolic-health ingredient in North American and European supplement lines over the past five years.

For a B2B formulator, the question is no longer “should we consider DNJ?” but rather: “Which DNJ specification, which dosage form, and which clinical evidence do we cite on the label and in our regulatory dossier?”

This guide walks through what the published evidence actually supports — and what it does not — so you can build a defensible formulation.

What DNJ is, and what it does in published studies

1-Deoxynojirimycin is an iminosugar naturally occurring in mulberry leaves (Morus alba). In vitro and animal-model studies show DNJ inhibits alpha-glucosidase at the intestinal brush border, slowing the digestion of complex carbohydrates and moderating postprandial glucose response.

Human clinical evidence has grown steadily. The most cited studies include:

A 2007 Journal of Ethnopharmacology study showing reductions in postprandial blood glucose in healthy volunteers after a standardized mulberry leaf extract.
A 2014 Nutrition Research paper on mulberry leaf extract combined with standard oral hypoglycemic agents in type 2 diabetes patients.
A 2021 systematic review and meta-analysis in Frontiers in Nutrition looking at mulberry leaf extract and glycemic control markers.

For B2B purposes, the take-away is: the mechanistic story (alpha-glucosidase inhibition) is plausible and replicated; the human clinical evidence is positive but still limited in scale. Your label claim should reflect what the evidence supports — typically a structure-function claim about carbohydrate metabolism — not a disease-treatment claim.

How much DNJ do you actually need

Most published human studies use DNJ doses in the range of 5–25 mg per serving, delivered as part of a mulberry leaf extract standardized to 1%, 2%, 5%, or 10% DNJ.

The practical formulation calculation:

A 500 mg mulberry leaf extract at 2% DNJ delivers 10 mg DNJ per serving.
A 250 mg extract at 5% DNJ delivers 12.5 mg DNJ per serving.
A 200 mg extract at 10% DNJ delivers 20 mg DNJ per serving.

Higher DNJ concentrations are more expensive per kilogram, but they let you hit the dose with smaller tablets or capsules — which is often a marketing advantage.

For weight-management products, mulberry DNJ is frequently combined with berberine, gymnemic acid (from gymnema), chromium, or cinnamon extract. The synergy is real but dose-dependent; do not assume that “more ingredients” is automatically better. Build your formula around the dose of DNJ you can defend.

What to look for on the supplier’s documentation

A serious mulberry leaf extract supplier should provide:

DNJ assay by HPLC or HPLC-MS, not just “polyphenols” or “flavonoids.” Iminosugars are not flavonoids, and the wrong assay method will give you meaningless numbers.
Lot-specific COA including DNJ, moisture, heavy metals, microbiology.
Origin and cultivar information — Morus alba leaf from specific cultivars (e.g., “Shandong origin, mulberry cultivar No. 1”) is more reproducible than generic “mulberry leaf extract.”
Solvent declaration — typically water-ethanol extraction. Anything else should be justified.
Stability data at 25 °C / 60% RH for 24 months.

If the supplier cannot provide any of these, treat the offer as speculative.

Formulation pitfalls to avoid

Pitfall 1: Mixing DNJ with high-dose alpha-glucosidase inhibitors
If your formula already contains acarbose or miglitol, adding DNJ creates a combined effect that has not been studied for safety at your combined dose. Talk to your regulatory consultant before combining.

Pitfall 2: Ignoring the bitterness
DNJ is mildly bitter. At 1%–2% DNJ, the bitterness is masked by other flavoring, but at 5%–10% DNJ in an unflavored capsule, you may get consumer complaints. Plan flavor masking or encapsulation if you go above 5%.

**Pitfall 3: Marketing over evidence
The weight-management and “blood sugar support” categories are crowded. Buyers who oversell DNJ’s evidence (e.g., claiming it “treats diabetes”) create regulatory exposure. Buyers who understate it lose to competitors. The honest middle is a structure-function claim tied to the dose you actually deliver.

A practical sourcing checklist

Before signing a supply agreement:

[ ] Supplier provides HPLC-MS DNJ chromatogram from an independent lab
[ ] DNJ assay is consistent across three consecutive lots (variance below 10%)
[ ] Heavy metals and microbiology panels are within destination-market limits
[ ] 24-month stability data is available at 25 °C / 60% RH
[ ] Origin and cultivar are documented

Looking for a DNJ supplier that can support 1%, 2%, 5%, or 10% standardized mulberry leaf extract — with documented origin, batch consistency, and full third-party verification? Reach out for our documentation pack.

Nourish Ingredients | ashely@nourishingr.com | www.nourishingr.net

Share: LinkedIn Twitter